Changes in appetite (QOL‐ACD item 8 score) by baseline characteristics of patients
cancer
ONCOLOGY, CANCER
We also compared the changes in appetite scores from baseline to week 12 between anamorelin and placebo in each subgroup, and the results are shown in Figure Subgroup analysis of changes in appetite (QOL‐ACD item 8) scores at 12 weeks according to sex, age, Alb, albumin; BMI, BW loss within 6 months, ECOG PS, and concomitant anticancer therapy. BMI, body mass index; BW, body weight; CI, confidence interval; CRP, C‐reactive protein; ECOG PS, Eastern Cooperative Oncology Group Performance Status; EGFR‐TKI, epidermal growth factor receptor tyrosine kinase inhibitor; LS, least‐squares; OR, odds ratio; QOL‐ACD, quality of life questionnaire for cancer patients treated with anticancer drugs.